title: [Viral clearance in wild-type hepatitis B virus after treatment with pegylated interferon alpha-2a].
authors.forename: M Pilar
authors.initials: MP
authors.lastname: López López
authors.forename: José Pablo
authors.initials: JP
authors.lastname: Rincón Fuentes
authors.forename: Susana
authors.initials: S
authors.lastname: Rabell Iñigo
authors.forename: Cristina
authors.initials: C
authors.lastname: González Pérez-Crespo
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Rodríguez Gil
authors.forename: Vanessa
authors.initials: V
authors.lastname: Jorge Vidal
authors.forename: Senador
authors.initials: S
authors.lastname: Morán Sánchez
authors.forename: M Isabel
authors.initials: MI
authors.lastname: Nicolás Del Prado
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D006510:Hepatitis B Antibodies / Q000097:blood; D006511:Hepatitis B Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000302:isolation & purification*; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D000077190:Interferon alpha-2; D000068576:Interferon beta-1b; D016898:Interferon-alpha / Q000627:therapeutic use*; D016899:Interferon-beta / Q000627:therapeutic use; D008111:Liver Function Tests; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000150:complications / Q000188:drug therapy; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D000068576:Interferon beta-1b; D011092:Polyethylene Glycols; D016899:Interferon-beta; C100416:peginterferon alfa-2a